Goyal Sharad, Shah Sneha, Khan Atif J, Danish Hasan, Haffty Bruce G
Department of Radiation Oncology, The Cancer Institute of New Jersey, Robert Wood Johnson Medical School, UMDNJ 195 Little Albany Street, New Brunswick, NJ 08903, USA.
ISRN Oncol. 2012;2012:896202. doi: 10.5402/2012/896202. Epub 2012 Dec 6.
Purpose. The purpose of this study was to analyze acute locoregional toxicity in patients with breast cancer receiving concurrent pazopanib and RT. Materials and Methods. Patients with breast cancer who received pazopanib in combination with radiation were identified and matched (2 : 1) to patients with breast cancer who did not receive pazopanib by use of chemotherapy, radiation field design, and radiation dose. Toxicity was scored by the Common Terminology Criteria for Adverse Events and statistical analysis was performed. Results. Grade 1 or 2 radiation dermatitis was seen in 100% and 84% of pazopanib and RT patients and matched controls respectively (P = NS). None of the patients receiving pazopanib and RT experienced ≥ grade 3 toxicity within the irradiated volume; three (16%) matched patients experienced a grade 3 skin reaction (P = 0.05). Interestingly, grade 1 or 2 hyperpigmentation was seen in 17% of pazopanib and RT patients and 60% of matched controls (P = 0.005). Conclusion. The addition of concurrent pazopanib and RT when treating the intact breast, chest wall, and associated nodal regions in breast cancer seems to be safe and well tolerated.
目的。本研究旨在分析接受帕唑帕尼与放疗联合治疗的乳腺癌患者的急性局部区域毒性。材料与方法。通过化疗、放疗野设计和放疗剂量，识别接受帕唑帕尼联合放疗的乳腺癌患者，并将其与未接受帕唑帕尼的乳腺癌患者进行匹配（2∶1）。采用不良事件通用术语标准对毒性进行评分并进行统计分析。结果。分别有100%接受帕唑帕尼与放疗联合治疗的患者和84%的匹配对照组患者出现1级或2级放射性皮炎（P=无显著性差异）。接受帕唑帕尼与放疗联合治疗的患者在照射野内均未出现≥3级毒性反应；3名（16%）匹配患者出现3级皮肤反应（P=0.05）。有趣的是，17%接受帕唑帕尼与放疗联合治疗的患者和60%的匹配对照组患者出现1级或2级色素沉着（P=0.005）。结论。在乳腺癌患者治疗完整乳房、胸壁及相关淋巴结区域时，联合使用帕唑帕尼与放疗似乎是安全且耐受性良好的。
